Drug developer ValiRx (LON:VAL) is making steady progress with the first in-man studies for lead compound VAL201.
The phase I trial is to assess tolerability and safety of the prostate cancer treatment as well as early signs of efficacy.
Results are expected by the end of the year and ValiRx said that all tasks that can or could affect the critical path of the VAL201 development programme are understood and controlled. “None is giving undue concern that the outcome or the timing of the study will be adversely affected,” it added.
Elsewhere, VAL101, the lead candidate deriving from the GeneICE platform, is progressing to the final pre-clinical "proof of concept" stage'. Pharmacokinetics, pharmacodynamics and preliminary toxicology studies are underway at Heidelberg University.
ValiRx added that having completed the programme for the Eurostars grant awarded to working on GeneICE, it had been notified it is also eligible for a new grant for work on VAL101 and biomarkers.
